Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.